HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Precision Therapy for Epilepsy Related to Brain Malformations.

Abstract
Malformations of cortical development (MCDs) represent a range of neurodevelopmental disorders that are collectively common causes of developmental delay and epilepsy, especially refractory childhood epilepsy. Initial treatment with antiseizure medications is empiric, and consideration of surgery is the standard of care for eligible patients with medically refractory epilepsy. In the past decade, advances in next generation sequencing technologies have accelerated progress in understanding the genetic etiologies of MCDs, and precision therapies for focal MCDs are emerging. Notably, mutations that lead to abnormal activation of the mammalian target of rapamycin (mTOR) pathway, which provides critical control of cell growth and proliferation, have emerged as a common cause of malformations. These include tuberous sclerosis complex (TSC), hemimegalencephaly (HME), and some types of focal cortical dysplasia (FCD). TSC currently represents the best example for the pathway from gene discovery to relatively safe and efficacious targeted therapy for epilepsy related to MCDs. Based on extensive pre-clinical and clinical data, the mTOR inhibitor everolimus is currently approved for the treatment of focal refractory seizures in patients with TSC. Although clinical studies are just emerging for FCD and HME, we believe the next decade will bring significant advancements in precision therapies for epilepsy related to these and other MCDs.
AuthorsAlissa M D'Gama, Annapurna Poduri
JournalNeurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics (Neurotherapeutics) Vol. 18 Issue 3 Pg. 1548-1563 (07 2021) ISSN: 1878-7479 [Electronic] United States
PMID34608615 (Publication Type: Journal Article, Research Support, N.I.H., Extramural, Review)
Copyright© 2021. The American Society for Experimental NeuroTherapeutics, Inc.
Chemical References
  • Anticonvulsants
  • MTOR Inhibitors
  • Everolimus
  • MTOR protein, human
  • TOR Serine-Threonine Kinases
  • Vigabatrin
Topics
  • Animals
  • Anticonvulsants (pharmacology, therapeutic use)
  • Epilepsy (epidemiology, genetics, therapy)
  • Everolimus (pharmacology, therapeutic use)
  • Humans
  • MTOR Inhibitors (pharmacology, therapeutic use)
  • Malformations of Cortical Development (epidemiology, genetics, therapy)
  • Precision Medicine (methods)
  • TOR Serine-Threonine Kinases (antagonists & inhibitors, genetics)
  • Vigabatrin (pharmacology, therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: